Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Camonsertib and low-dose gemcitabine demonstrated preliminary clinical activity, but due to challenging tolerability further evaluation is warranted to identify the optimal dosing regimen and subset of patients who may benefit most from this combination.
Authors
- Martin Højgaard (ORCID: https://orcid.org/0000-0003-1850-535X)
- Ian M. Silverman (ORCID: https://orcid.org/0000-0003-3819-6726)
- Emeline Bacqué
- E. Fontana
- Michal Zimmermann (ORCID: https://orcid.org/0000-0002-9955-1675)
- S. Lheureux
- María Koehler (ORCID: https://orcid.org/0000-0002-4477-9621)
- Anne Roulston (ORCID: https://orcid.org/0000-0003-4814-8242)
- Joseph D. Schonhoft (ORCID: https://orcid.org/0000-0002-5860-5040)
- Adrian J. Fretland (ORCID: https://orcid.org/0000-0003-4720-1662)
- E. Lee
- Victoria Rimkunas (ORCID: https://orcid.org/0000-0003-4263-2009)
- Ezra Y. Rosen (ORCID: https://orcid.org/0000-0002-5289-1541)
- Danielle Ulanet (ORCID: https://orcid.org/0009-0001-7754-9224)
- Gregory M. Coté (ORCID: https://orcid.org/0000-0003-0181-886X)
- Prof Ruth Plummer
- Benedito A. Carneiro
- Kezhen Fei
- Devalingam Mahalingam
- Niharika B. Mettu
- Li Li
- Prasamit Baruah
- Timothy A. Yap
- Julia Yang
- Gabriela Gomez
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Duke University (US)
- Sarah Cannon Research Institute (GB)
- Brown University (US)
- Princess Margaret Cancer Centre (CA)
- Rigshospitalet (DK)
- Sir Bobby Robson Foundation (GB)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
- Duke University Hospital (US)
- St. Laurent Institute (US)
- Xilio Therapeutics (United States) (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2240
- Primary Topic
- DNA Repair Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Massachusetts General Hospital
- Memorial Sloan-Kettering Cancer Center
- Regeneron Pharmaceuticals
- Actuate Therapeutics
- Eisai
- Astellas Pharma
- University of Texas MD Anderson Cancer Center
- Duke Cancer Institute